Document Detail

Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers.
MedLine Citation:
PMID:  15141745     Owner:  NLM     Status:  MEDLINE    
To examine the bioavailability of rifampicin formulations produced in Indonesia, we conducted a single-dose, double-blind, cross-over bioavailability study. Antituberculosis drugs from three Indonesian manufacturers and one international manufacturer were compared in 12 healthy Indonesian subjects. Out of three local manufacturers, two showed equal bioavailability compared to the reference standard, and one showed slightly lower bioavailability (ratio 0.86; 90% confidence interval 0.80-0.91) and substandard rifampicin content of drug preparations. Plasma rifampicin concentrations in this study were more than three-fold higher than concentrations recently found in tuberculosis patients in Indonesia, which suggests that unknown (disease-related) determinants may reduce the bioavailability of rifampicin formulations.
R van Crevel; R H Nelwan; F Borst; E Sahiratmadja; J Cox; W van der Meij; M de Graaff; B Alisjahbana; W C de Lange; D Burger
Related Documents :
22335885 - The effects of splinting on shoulder function in adult burns.
2086165 - Effects of enalapril in normotensive patients with stable effort angina: a double blind...
2647495 - Objective evaluation of gallopamil in patients with chronic stable angina. exercise tes...
3073525 - The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patie...
1758655 - Development of an exercise program for older adults: pre-exercise testing, exercise pre...
6488225 - Diastolic time during exercise in normal subjects and in patients with coronary artery ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease     Volume:  8     ISSN:  1027-3719     ISO Abbreviation:  Int. J. Tuberc. Lung Dis.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-05-14     Completed Date:  2004-08-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9706389     Medline TA:  Int J Tuberc Lung Dis     Country:  France    
Other Details:
Languages:  eng     Pagination:  500-3     Citation Subset:  IM    
Department of Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antitubercular Agents / pharmacokinetics*
Biological Availability
Cross-Over Studies
Double-Blind Method
Reference Values
Rifampin / pharmacokinetics*
Reg. No./Substance:
0/Antitubercular Agents; 13292-46-1/Rifampin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical characteristics of 110 miliary tuberculosis patients from a low HIV prevalence country.
Next Document:  Indigenous NGO involvement in TB treatment programmes in high-burden settings: experiences from the ...